SCHEMBL3609410

SCHEMBL3609410

N#Cc1cc(-c2ccnc(Cl)c2)[nH]c1N1CCNCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK9 P50750 4/20 0.49
CDC7 O00311 3/20 0.49
PIM1 P11309 3/20 0.49
PRKD1 Q15139 3/20 0.43
PRKCA P17252 1/20 0.43
PRKCD Q05655 1/20 0.43
ROCK2 O75116 2/20 0.41
ROCK1 Q13464 1/20 0.41
CDC42BPB Q9Y5S2 1/20 0.41
MAP4K4 O95819 1/20 0.41
CDK2 P24941 1/20 0.41
MAPKAPK2 P49137 1/20 0.41
GSK3B P49841 1/20 0.41
HIPK2 Q9H2X6 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.41
ALDH1A1 P00352 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3617474 0.99 CDK9 (0.48) CDK9CDC7PIM1PRKD1PRKCA
SCHEMBL3618285 0.90 ROCK2 (0.40) CDK9CDC7PIM1ROCK2ROCK1
SCHEMBL3618175 0.87 TBK1 (0.45) ROCK2ROCK1CDC42BPBKDM4ETBK1
SCHEMBL3617304 0.85 KCNMA1 (0.44) CDK9CDC7PIM1ROCK2MAP4K4
SCHEMBL3608996 0.84 CDC7 (0.38) CDK9CDC7PIM1ROCK2MAP4K4
SCHEMBL3618751 0.80 PIM1 (0.47) CDK9CDC7PIM1PRKD1PRKCD
SCHEMBL3618749 0.80 PIM1 (0.47) CDK9CDC7PIM1PRKD1PRKCD
SCHEMBL3615497 0.80 KCNMA1 (0.48) CDC7ROCK2ROCK1CDC42BPBMAP4K4
SCHEMBL3617538 0.79 PIM1 (0.44) CDK9CDC7PIM1PRKD1ROCK2
SCHEMBL13408118 0.79 PRKD1 (0.44) CDK9CDC7PIM1PRKD1ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105664-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-04-29 US disclosed
US-20100105664-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-04-29 US disclosed
EP-2069333-A1 PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES Novartis Ag (CH) 2009-06-17 EP disclosed
WO-2008034600-A1 PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES NOVARTIS AG (CH) 2008-03-27 WO disclosed
WO-2008034600-A1 PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES NOVARTIS AG (CH) 2008-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105664-A1 ORGANIC COMPOUNDS SLCO1B3, SLCO1B1, SLC10A6 CDK9 1238/4885CDC7 4089/4885PIM1 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.